L19

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Retrieved on: 
Monday, October 16, 2023
BSE, ANZ, CSO, MD, HR, Toxicity, L19, Sun Pharma, Melanoma, BIT, NSE, Phase, Reuters, Patient, Neoadjuvant therapy, IL2, RFS, Skin, Medical imaging, Pharmaceutical industry, Jaden Philogene

The study compared neoadjuvant intratumoral Nidlegy™ (Daromun) followed by surgery (treatment arm) vs. surgery alone (control arm).

Key Points: 
  • The study compared neoadjuvant intratumoral Nidlegy™ (Daromun) followed by surgery (treatment arm) vs. surgery alone (control arm).
  • According to the protocol, the primary endpoint of the study was the Recurrence-Free Survival (RFS) assessed per Blinded Independent Central Review (BICR) for patients treated with Nidlegy™, compared to the control arm.
  • At median follow-up of 27.6 months in both groups, the study met its primary endpoint with a statistically significant and clinically meaningful improvement in RFS of the treatment arm compared to the control arm.
  • Prof. Dario Neri, co-founder, CEO and CSO of Philogen, commented: "We are extremely pleased to announce positive topline data emerging from our PIVOTAL program in locally advanced resectable melanoma.

Philogen Provides Corporate Update

Retrieved on: 
Thursday, June 23, 2022
Soft-tissue sarcoma, R, Intellectual property, L19, Therapy, GMP, IPO, PSMA, Tissue, Survival, TNF, Cancer, Research, Blood, COVID-19, Lomustine, Antigen, Disease, BST, Cleavage, ORR, IL2, MGMT, Patient, Group, Ligand, Glioblastoma, Chemical library, Neoplasm, Pharmaceutical industry, Medical imaging, Fine chemical, Vaccine, Fibronectin, Jaden Philogene-Bidace

Siena (Italy), 23 June 2022 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics, provides an update regarding recent corporate developments.

Key Points: 
  • Siena (Italy), 23 June 2022 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics, provides an update regarding recent corporate developments.
  • Prof. Dr. Dario Neri, Chief Executive Officer of Philogen commented: "Philogen has made significant progress over the past few months as we continue investing our IPO proceeds to strengthen our GMP manufacturing capacity and speed up patient enrolment in clinical trials.
  • Nidlegy is a pharmaceutical product, proprietary to Philogen, consisting of two active ingredients, L19IL2 and L19TNF.
  • Philogen is an Italian-Swiss company active in the biotechnology sector, specialized in the research and development of pharmaceutical products for the treatment of highly lethal diseases.

Philogen Reports Full Year 2021 Results and Provides Corporate Update

Retrieved on: 
Friday, April 1, 2022
Chemical library, European Journal of Nuclear Medicine and Molecular Imaging, Disease, Blood, EDA, Glioblastoma, Cash Cash, Therapy, Ligand, Group, L19, Interleukin, ORR, Nuclear medicine, Initial public offering, Mouse, EDB, MGMT, Survival, Research, Glioma, Lomustine, Observation, Antigen, Neoplasm, IL12, Cancer, Tissue, TNF, European Journal, Inflammation, Google Images, Intellectual property, CRO, Molecular imaging, News, IL2, BST, Soft-tissue sarcoma, IPO, IL10, Patient, Partnership, Backhaus, Pharmaceutical industry, Medical imaging, Fine chemical, Cryptocurrency, Vaccine, Jaden Philogene-Bidace, Pfizer, Fibronectin, Phase

In 2022 Philogen will limit cash burn (or possibly have no cash burn), due to existing and new partnerships, despite increased spending for clinical trials.

Key Points: 
  • In 2022 Philogen will limit cash burn (or possibly have no cash burn), due to existing and new partnerships, despite increased spending for clinical trials.
  • Siena (Italy), 1 April 2022 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics, provides an update regarding the Companys full year 2021 results and recent corporate developments.
  • "We are excited for the great progress we have made following our listing on the Italian Stock Exchange in March 2021.
  • Philogen has a rich pipeline of late-stage clinical assets and continues to innovate by generating new prototypes, commented Prof. Dr. Dario Neri, Chief Executive Officer of Philogen.

Philogen Provides Corporate Update

Retrieved on: 
Friday, November 12, 2021
Molecule, Phase, Intellectual property, Initial public offering, Cancer, Ligand, National academy, L19, News, EDA, Tissue, PET, Neoplasm, IL10, Clinical trial, Antigen, Gallium, Interleukin, EST, CEO, Small molecule drug conjugate, Disease, Department, Heterotrimeric G protein, Teaching hospital, Inflammation, BST, MGMT, Research, IL2, FAP, Blood, Lomustine, Therapy, Collection, Chemical library, TNF, Patient, Group, Melanoma, Glioblastoma, Fine chemical, Medical imaging, Vaccine, Pharmaceutical industry, Cryptocurrency

Philogens management team will hold a Webinar to discuss the news on November 12th, 2021, at 11:00 EST / 16:00 BST / 17:00 CEST (Please find the link to this Webinar here )

Key Points: 
  • Philogens management team will hold a Webinar to discuss the news on November 12th, 2021, at 11:00 EST / 16:00 BST / 17:00 CEST (Please find the link to this Webinar here )
    Siena (Italy), 12 November 2021 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics provides an update regarding the Companys Third Quarter Results and recent corporate developments.
  • Dario Neri, CEO of Philogen, commented on the results for the quarter and the evolution of the business:
    "The past few months have been very important for Philogen, and I am delighted to provide an update on our pipeline and our financial position.
  • Nidlegy is a pharmaceutical product, proprietary to Philogen, consisting of two active ingredients, L19-IL2 and L19-TNF.
  • Philogen has discovered yet another potential clinical candidate that will expand the clinical stage pipeline over the next few years.

Philogen Provides Corporate Update

Retrieved on: 
Wednesday, September 29, 2021
Melanoma, Nominal interest rate, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TNF, Population, L19, FAP, DNA-encoded chemical library, Contract research organization, Food and Drug Administration, AIFA, GMP, Squamous cell carcinoma, Food, National academy, European Medicines Agency, CEO, Group, Teaching hospital, Disease, Ligand, Soft-tissue sarcoma, Dacarbazine, Clinical trial, Neoplasm, Therapy, Cancer, Gallium, Nuclear medicine, Marketing, Company, Heterotrimeric G protein, Medicine, Tissue, Data, Intellectual property, Department, Lomustine, Patient, IL2, PSA, IDH, Antigen, Research, Blood, Pharmaceutical industry, Fine chemical, Vaccine, Medical imaging, Medical device

Clinical experience with OncoFAP confirms preclinical results, recently published in Proceedings of the National Academy of Sciences U.S.A.

Key Points: 
  • Clinical experience with OncoFAP confirms preclinical results, recently published in Proceedings of the National Academy of Sciences U.S.A.
    Siena (Italy), 29 September 2021 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics announces its Interim Results for the six month period ended 30th June 2021 and provides an update regarding recent corporate developments.
  • Nidlegy is a pharmaceutical product, proprietary to Philogen, consisting of two active ingredients, L19-IL2 and L19-TNF.
  • Additional countries are planned to be involved in Phase II studies;
    Fibromun is a pharmaceutical product, proprietary to Philogen, consisting of the L19 antibody fused to TNF.
  • OncoFAP is a small organic molecule, proprietary to Philogen group, with affinity for Fibroblast Activation Protein (FAP).

Philogen Announces R&D Program Update

Retrieved on: 
Friday, July 2, 2021
Branches of biology, Medical specialties, Clinical medicine, Cytokines, Immunology, Inflammatory cytokine, Clusters of differentiation, Cytokine, Tumor necrosis factor, Immunotherapy, E-selectin, L19

A full pipeline update will be made to the market on 28 September, 2021, in the Companys Half Year results announcement.

Key Points: 
  • A full pipeline update will be made to the market on 28 September, 2021, in the Companys Half Year results announcement.
  • Fibromun (L19TNF), wholly-owned by Philogen, is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine).
  • The results from these studies will provide the basis for a pivotal clinical program in selected cancer types.
  • Philogen accepts no responsibility for the data protection policy and customer information of websites of third parties and shall not be liable for the content or web pages of third parties which are linked to the Philogen website, or which display the Philogen website in frames.

Tanzanian Gold announces an upper level intercept of 48m (incl. 5m @6.6g/t and 1.0M @ 16.8 g/t ) and a deeper intercept of 13.4m (incl. 8.0m @ 4.9 g/t) in the first hole of the Phase III deep drilling program testing the underground potential at Buckreef

Retrieved on: 
Wednesday, February 26, 2020
Mineralization, Nitrogen, Soil science, L19, Minde

The results summarized below from Hole L19-1 indicate that the mineralization encountered at surface extends at least 500m vertically at depth and is still open.

Key Points: 
  • The results summarized below from Hole L19-1 indicate that the mineralization encountered at surface extends at least 500m vertically at depth and is still open.
  • The intersection at 622m in this hole appears to be just a slice of the entire Mineralized Zone target.
  • SGS Canada has collected a comprehensive suite of samples from deeper levels that are presently en-route to Canada and to Queens University for stress testing.
  • The sample chain of custody is managed by the Buckreef technical team under the supervision of Anthony Minde.